Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Market Dynamics | Explore Progyny's position in the expanding fertility benefits market, projected to reach $50 billion by 2030, and its innovative approach to comprehensive coverage |
Financial Challenges | Delve into Progyny's recent setbacks, including the loss of a major client and lowered revenue guidance, balanced against its strong cash position and profitability |
Strategic Expansion | Learn about Progyny's foray into maternity and menopause programs, potentially offsetting recent losses and contributing significantly to future revenue growth |
Analyst Outlook | Discover varied analyst perspectives, with price targets ranging from $22 to $30, reflecting both optimism about long-term potential and concerns over near-term headwinds |
Metrics to compare | PGNY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPGNYPeersSector | |
---|---|---|---|---|
P/E Ratio | 36.7x | −0.1x | −0.5x | |
PEG Ratio | −5.02 | 0.04 | 0.00 | |
Price/Book | 3.8x | 0.8x | 2.6x | |
Price / LTM Sales | 1.6x | 0.9x | 3.3x | |
Upside (Analyst Target) | 24.7% | 43.6% | 43.4% | |
Fair Value Upside | Unlock | 14.6% | 7.1% | Unlock |